The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …

Background In recent times, pancreatitis has been one of the most frequently reported
adverse events for sodium-glucose cotransporter-2 (SGLT2) inhibitors. Aim To evaluate the …

Background The existing evidence from pre-and post-marketing studies is conflicting on the
risk of pancreatic events for anti-diabetic medications. Research design and methods A …

Introduction Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic
agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug–drug …

Introduction In adults, sodium-glucose cotransporter type 2 inhibitors have revolutionised the
treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. Objective We …

Purpose This study was undertaken to evaluate the potential risk of acute pancreatitis with
empagliflozin in patients with type 2 diabetes (T2D) newly initiating empagliflozin. Methods …

Background: The Food and Drug Administration issued a warning on the risk of acute kidney
injury and a signal of nephrolithiasis for patients using sodium–glucose co-transporter 2 …

Background: Drugs are related with various adverse drug reactions (ADRs), however, many
unexpected ADRs of drugs are reported through post-marketing surveillance. Aim: The …

Background Studies have found an increased risk of pyoderma gangrenosum associated
with rituximab. The structural properties and pharmacological action of rituximab may affect …

Acute pancreatitis has been considered a rare potential adverse effect of sodium-glucose co-
transporter-2 inhibitors (SGLT-2is), a new class of medications recently approved for use as …